Go Pro
→ Buy These Stocks Before August 31st (From TradeSmith) (Ad)tc pixel
NASDAQ:ETON

Eton Pharmaceuticals Q3 2018 Earnings Report

Eton Pharmaceuticals logo
$63.47 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q3 2018
Date
12/20/2018
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Eton Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Eton Pharmaceuticals Earnings Headlines

Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/eton-pharmaceuticals-eton-q2-2026-232703174.html
Eton Pharmaceuticals (NASDAQ:ETON) Hits New 1-Year High on Better-Than-Expected Earnings
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963213
Silicon Valley Insider: "Forget AI Stocks"
A 25-year Silicon Valley veteran who recommended Nvidia before its 32,000 percent run says the next wave of AI gains wont come from Nvidia, Tesla, or SpaceX. He points to a detail buried on page 37 of the SpaceX IPO filing, tied to Elon Musks plans for 1 million AI satellites, 1 billion humanoid robots, and 200 billion AI chips a year. He says one overlooked sector could benefit most from this spending, and has identified a company trading under $1 that may factor into Musks supply chain.tc pixel
August 24 at 1:00 AM  |  Brownstone Research (Ad)
Eton Pharmaceuticals Shares Rise on Swing to 2Q Profit, Outlook Raise
August 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/eton-pharmaceuticals-shares-rise-on-swing-to-2q-profit-outlook-raise-a4edb5b8
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
August 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PROK/pressreleases/3852811/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prokidney-prok-eton-pharmaceuticals-eton-and-dyadic-international-dyai/
HC Wainwright Has Pessimistic View of ETON FY2027 Earnings
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961695
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets.

Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.

View Eton Pharmaceuticals Profile
Earnings Tools